Company Encyclopedia
View More
name
SC Pharmaceuticals
002693.SZ
Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmaceuticals Co., Ltd.
3.159 T
002693.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking169/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-10.42%D
    • Profit Margin-19.89%D
    • Gross Margin69.99%A
  • Growth ScoreB
    • Revenue YoY19.66%B
    • Net Profit YoY50.56%B
    • Total Assets YoY-3.25%D
    • Net Assets YoY-13.28%E
  • Cash ScoreC
    • Cash Flow Margin-502.79%E
    • OCF YoY19.66%B
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreC
    • Gearing Ratio49.32%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ST SC Pharmaceuticals: Passed the drug GMP compliance inspection

    ST SC Pharmaceuticals announced that the company recently received the "Drug GMP Compliance Inspection Notification" issued by the Hainan Provincial Drug Administration. The inspection scope includes lyophilized powder injections, active pharmaceutical ingredients, and related production lines. The inspection date is from June 11 to 13, 2025, and the inspection conclusion meets the requirements of the Good Manufacturing Practice (GMP) for drug production quality management. This successful inspection indicates that the company's production quality management system complies with the requirements of the Good Manufacturing Practice for drug production, which is beneficial for maintaining stable production capacity and meeting market demand

    Zhitong·
    SZ
    002693
    -1.84%
    Zhitong·
    SZ
    002693
    -1.84%

    ST SC Pharmaceuticals released its half-year performance, with a net loss attributable to shareholders of 18.4666 million yuan, an increase of 8.97%

    ST SC Pharmaceuticals released its semi-annual report for 2025, with operating revenue of 84.1221 million yuan, a year-on-year decrease of 11.35%. The net loss attributable to shareholders of the listed company was 18.4666 million yuan, a year-on-year increase of 8.97%. The net loss after deducting non-recurring gains and losses was 21.0158 million yuan, a year-on-year increase of 18.34%. The basic loss per share was 0.0445 yuan

    Zhitong·
    SZ
    002693
    -1.84%
    Zhitong·
    SZ
    002693
    -1.84%

    ST SC Pharmaceuticals: Eptinezumab injection has obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia

    ST SC Pharmaceuticals recently obtained the marketing authorization for Eptifibatide Injection issued by the Therapeutic Goods Administration (TGA) of Australia. This drug is suitable for patients undergoing non-emergency percutaneous coronary intervention, as well as for the treatment of unstable angina or non-Q wave myocardial infarction. This authorization will help the company expand its overseas market and improve its performance

    Zhitong·
    SZ
    002693
    -1.84%
    Zhitong·
    SZ
    002693
    -1.84%

    ST SC Pharmaceuticals: Injectable Paclitaxel (Albumin-Bound) ANDA approved for market by the U.S. FDA

    ST SC Pharmaceuticals recently announced that the company has received approval from the U.S. FDA for the abbreviated new drug application (ANDA) for injectable paclitaxel (albumin-bound). This product has undergone comprehensive technical review, confirming its bioequivalence and therapeutic equivalence to the original drug. Injectable paclitaxel (albumin-bound) forms nanoparticles by encapsulating paclitaxel in albumin, significantly reducing cytotoxic side effects, enhancing anti-tumor effects, and providing targeting capabilities to direct release to tumor cells

    Zhitong·
    SZ
    002693
    -1.84%
    Zhitong·
    SZ
    002693
    -1.84%

    ST SC Pharmaceuticals: Injectable Bivalirudin has obtained market approval from the Therapeutic Goods Administration (TGA) of Australia

    ST SC Pharmaceuticals recently obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia for injectable bivalirudin. This drug is used for the treatment of patients with moderate to high-risk acute coronary syndrome, applicable to those with unstable angina and non-ST elevation myocardial infarction, and can be used in combination with aspirin and P2Y12 antagonists

    Zhitong·
    SZ
    002693
    -1.84%
    Zhitong·
    SZ
    002693
    -1.84%
    © 2025 Longbridge｜Disclaimer